FY2028 EPS Estimates for Haemonetics Increased by Analyst

Haemonetics Corporation (NYSE:HAE - Free Report) - Equities researchers at Zacks Research upped their FY2028 earnings per share estimates for shares of Haemonetics in a research report issued to clients and investors on Monday, July 7th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings per share of $6.03 for the year, up from their previous estimate of $6.02. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share.

HAE has been the topic of several other research reports. Needham & Company LLC dropped their target price on Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Citigroup raised Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 target price on the stock in a research report on Wednesday. Barrington Research reissued an "outperform" rating and set a $95.00 price target on shares of Haemonetics in a research report on Friday. JMP Securities reissued a "market outperform" rating and set a $100.00 price target on shares of Haemonetics in a research report on Tuesday, May 20th. Finally, Robert W. Baird initiated coverage on Haemonetics in a research report on Thursday, June 26th. They set an "outperform" rating and a $87.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and a consensus target price of $97.30.

Haemonetics Stock Down 3.4%

HAE traded down $2.62 on Thursday, hitting $75.55. 660,605 shares of the company were exchanged, compared to its average volume of 676,026. Haemonetics has a 12 month low of $55.30 and a 12 month high of $94.99. The company has a market cap of $3.63 billion, a PE ratio of 22.82, a PEG ratio of 1.22 and a beta of 0.39. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.62. The stock's fifty day moving average is $70.73 and its 200-day moving average is $67.98.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. The firm had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The company's revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.90 earnings per share.

Institutional Investors Weigh In On Haemonetics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. TD Waterhouse Canada Inc. bought a new position in Haemonetics during the 4th quarter worth $25,000. Quarry LP raised its position in Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock worth $31,000 after purchasing an additional 192 shares during the last quarter. UMB Bank n.a. raised its position in Haemonetics by 91.7% during the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock worth $50,000 after purchasing an additional 320 shares during the last quarter. Covestor Ltd raised its position in Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after purchasing an additional 439 shares during the last quarter. Finally, Whittier Trust Co. bought a new position in Haemonetics during the 4th quarter worth $62,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.